cudc-305
Small moleculeexperimental
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2010 (NCT01168752)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
HSP90AB2P inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)c1cc2c(cc1Sc1nc3c(N)nccc3n1CCNCC(C)(C)C)OCO2- Mol. weight
- 442.59 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2419346 ↗
Also known as
- cudc305
- cudc 305
- cudc-305
- debio 0932
- debio 0932
- debio 0932
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03675542 | Phase 1 | Nov 1, 2018 | Aarhus University |
| NCT01714037 | Phase 1 | Aug 1, 2012 | Centre Georges Francois Leclerc, Debiopharm, INC Research, Newcastle University, Universidad Autonoma de Barcelona, Universidad Autonoma de Madrid, University of Toulouse |
| NCT01168752 | Phase 1 | Apr 1, 2010 | Debiopharm |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Debiopharm | For profit | 2 | 2 | 1 | 2010 |
| Aarhus University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Centre Georges Francois Leclerc | Academic/Hospital | 1 | 0 | 1 | 2012 |
| INC Research | For profit | 1 | 0 | 1 | 2012 |
| Newcastle University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Universidad Autonoma de Barcelona | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Universidad Autonoma de Madrid | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Toulouse | Academic/Hospital | 1 | 0 | 1 | 2012 |
8 organizations
Page 1 / 1